Skip to content

Study · Non-randomized trial · n = 36 · 2005

1 result

[Use of the Gepon immunomodulator for ulcerative colitis treatment].

Malakhova NS, Pichugin AV, Khalif IL, Ataullakhanov RI

Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology1 Jan 2005Cited by 1 (Europe PMC)

PMID15991847 (opens in a new tab)PepBankPUB-15991847
Publisher pageAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with resistant distal ulcerative colitis, 83.3% had clinical and endoscopic amelioration and overcame resistance to basic anti-inflammatory drugs after Gepon.

    In plain wordsIn patients with resistant ulcerative colitis, most (83.3%) improved clinically and on endoscopy after Gepon and overcame resistance to basic anti-inflammatory drugs.

    Peptide
    Gepon
    Outcome
    IncreaseClinical and endoscopic amelioration and overcoming of drug resistance
    Study

    n = 36

    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    Patients with clinical and endoscopic amelioration
    83.3%
    Resistant distal ulcerative colitis, after Gepon

    Source sentences

    Summary
    Most of the patients (83.3%) had clinical and endoscopic amelioration after taking Gepon and managed to overcome the resistance to basic anti-inflammatory drugs.
    1 context sentence
    Summary · context
    The efficacy of the Gepon immunomodulator was studied in 36 patients with ulcerative colitis (UC) having distal lesions in the resistant form.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.